Default company panoramic image
Dd1c9c42 0273 4c3b a2e5 42fb3d6db396

Chelexa BioSciences, inc.

Chelexa is developing and commercializing unique and disruptive topical drug products that prevent serious infections and save lives.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Newton, MA, USA
  • Currency USD
  • Founded June 2011
  • Employees 1
  • Website

Company Summary

Chelexa develops and commercializes unique topically applied drug products that prevent serious infections in surgical sites and chronic wounds. Our technology targets over 10 million US patients and a $10 billion market. Our first product, BioLexa, combines 2 FDA approved drugs in a proprietary formulation to prevent bacterial proliferation, colonization and biofilm related infections. BioLexa is planned to launch in 2016.


  • Default avatar
    Kenneth L Rice Jr., MBA, JD, LLM
    Chief Executive Officer

    Alseres Pharmaceuticals, Aderis Pharmaceuticals, Pentose Pharmaceuticals, Macrochem, Unisyn Technologies, Millipore. Mr. Rice has over 20 years of executive e He has raised over $150M in capital and has led global manufacturing, HR, Finance, IT, engineering and sales and marketing organizations

  • Default avatar
    Andrew Herr, PhD
    Co-founder & Chief Scientific Advisor

    Associate Professor
    Ohio Eminent Scholar, University of Cincinnati College of Medicine
    40+ Peer Reviewed Publications
    2 Patents. Dr. Herr's work on biofilms is unrivaled in the research community.

  • Default avatar
    Robert Kirsner, MD, Ph.D.
    Medical Advisor

    University of Miami Dermatology and Cutaneous Surgery Center